Juvenile myelomonocytic leukemia overview: Difference between revisions
No edit summary |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 8: | Line 8: | ||
{{Hematological malignancy histology}} | {{Hematological malignancy histology}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Latest revision as of 16:39, 9 August 2012
|
Juvenile myelomonocytic leukemia Microchapters |
|
Differentiating Juvenile myelomonocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Juvenile myelomonocytic leukemia overview On the Web |
|
American Roentgen Ray Society Images of Juvenile myelomonocytic leukemia overview |
|
Risk calculators and risk factors for Juvenile myelomonocytic leukemia overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Juvenile myelomonocytic leukemia (JMML) is a serious chronic leukemia (cancer of the blood) that affects children mostly aged 4 and under. The average age of patients at diagnosis is 2 years old. The World Health Organization has included JMML in the category of Myelodysplastic and Myeloproliferative disorders.[1] The name JMML now encompasses all diagnoses formerly referred to as Juvenile Chronic Myeloid Leukemia (JCML), Chronic Myelomonocytic Leukemia of Infancy, and Infantile Monosomy 7 Syndrome.